DITROPAN XL TABLET (EXTENDED-RELEASE)

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

OXYBUTYNIN CHLORIDE

Fáanlegur frá:

JANSSEN INC

ATC númer:

G04BD04

INN (Alþjóðlegt nafn):

OXYBUTYNIN

Skammtar:

15MG

Lyfjaform:

TABLET (EXTENDED-RELEASE)

Samsetning:

OXYBUTYNIN CHLORIDE 15MG

Stjórnsýsluleið:

ORAL

Einingar í pakka:

100

Gerð lyfseðils:

Prescription

Lækningarsvæði:

Antimuscarinics

Vörulýsing:

Active ingredient group (AIG) number: 0114692005; AHFS:

Leyfisstaða:

CANCELLED PRE MARKET

Leyfisdagur:

2017-08-03

Vara einkenni

_Ditropan XL_apm.doc _
_ _
_1 of _
26
_ _
PRODUCT MONOGRAPH
PR
DITROPAN XL
*
oxybutynin chloride
Extended-release Tablets, USP
5 mg, 10 mg and 15 mg
Anticholinergic/Antispasmodic Agent
This Product Monograph is the exclusive property of Janssen-Ortho Inc.
It may not be copied in whole or in part without the written
permission of Janssen-Ortho Inc.
Janssen-Ortho Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
www.janssen-ortho.com
Date of Revision:
March 03, 2009
SUBMISSION CONTROL NUMBER: 126559
* All trademark rights used under license
© 2009 JANSSEN-ORTHO Inc.
_Ditropan XL_apm.doc _
_ _
_2 of _
26
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................6
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND
ADMINISTRATION..............................................................................11
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND
STABILITY..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15